NSE - In-principle approval for Bonus
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shilpa Medicare has received in-principle approval from NSE to allot 9,77,90,908 bonus equity shares of Re.1 each in the ratio of 1:1, meaning one new share for every one share held. The record date for determining eligible shareholders is Friday, 03 October 2025, which was earlier intimated on 22 August 2025. This is a procedural approval from the exchange, conditional on statutory and regulatory clearances from SEBI, RBI, MCA, and others. The bonus doubles the number of outstanding shares held by existing shareholders.
Positive for existing shareholders — on the record date, each shareholder will receive one additional share for every share held, effectively doubling their share count (though the share price typically adjusts downward proportionally). The 1:1 bonus signals management confidence but also expands the share base significantly.